EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 226 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR ΚΑΡΚΙΝΟΣ ΠΑΧΕΩΣ ΕΝΤΕΡΟΥ February 10, 2019 “Giving something back”: our supporters are the beating heart of what... August 17, 2022 April is Occupational Therapy (OT) Month- What is OT and how... April 8, 2021 ΠΟΝΟΣ March 8, 2019 Load more HOT NEWS Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... Efficacy and Safety of Trastuzumab and Pertuzumab in Combination with FLOT... Meeting Cancer Survivors’ Psychosocial Health Needs: A Conversation with Dr. Patricia... FDA Approves First Immunotherapy Treatment For Breast Cancer
